TELA Bio, Inc.
NASDAQ:TELAMedical - Devices
+$0.09 today
- Market cap
- $51.00M
- Beta
- 1.36
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$0.72
Volume 0.22M
Average 0.17M
TELA Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
TELA Bio, Inc.NASDAQ: TELA
Net Receivables · Q2 FY2026 · quarter ended Jun 2026
Net receivables falls 23.1% from a year ago
Net receivables stood at $9.64M at the end of Q2 FY2026, down 23.1% from a year earlier and down 0.8% from the prior quarter. Over 3 fiscal years it compounded at +16.0% a year.
Context
- Net receivables amounted to 16.1% of total assets at the end of Q2 FY2026, down 2.4 pp from a year earlier.
- Net receivables increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps falling in the next quarterly balance sheet after a -23.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 10.35M USD
- Year-over-year change
- +2.5%
- 4-year CAGR
- +25.0%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.35M | +2.5% |
| FY2024 | 2024-12-31 | 10.1M | +3.7% |
| FY2023 | 2023-12-31 | 9.74M | +47.1% |
| FY2022 | 2022-12-31 | 6.62M | +56.4% |
| FY2021 | 2021-12-31 | 4.23M | — |
Net Receivables vs competitors
How TELA compares with its peers on the latest reported figures
- TELA's Jun 2026 net receivables of $9.64M is the highest of the 9 companies compared; the peer median is $683K.
- Its year-over-year change of -23.1% is the highest of 4, against a peer median of -80.1%.
- Net receivables amounts to 16.1% of total assets for TELA, versus a peer median of 4.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $9.64M | -23.1% | +16.0% | 16.1% | |
| Mar 2026 | $5.35M | — | +407.4% | 17.3% | |
| Mar 2026 | $3.58M | -80.1% | -29.6% | 6.9% | |
| Mar 2026 | $2.72M | — | — | 12.4% | |
MDAISpectral AI, Inc. | Mar 2026 | $1.19M | -43.7% | -24.2% | 6.7% |
| Mar 2026 | $181K | — | +184.4% | 1.5% | |
| Mar 2026 | $15.29K | — | -3.1% | 0.1% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | -100.0% | -70.3% | 0.0% | |
| Peer median (excluding TELA) | $683K | -80.1% | -13.7% | 4.1% | |
Competitors are the stored peer set for TELA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 43.93M | 42.02M | 46.73M | 52.67M | 50.85M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 4.23M | 6.62M | 9.74M | 10.1M | 10.35M |
| Inventory | 7.66M | 11.79M | 13.16M | 12.78M | 11.02M |
| Other Current Assets | 0 | 2.02M | 2.1M | 2.52M | 3.37M |
| Total Current Assets | 59.06M | 62.45M | 71.73M | 78.07M | 75.58M |
| Property, Plant & Equipment (Net) | 1.19M | 2.91M | 3.94M | 4.08M | 3.73M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 2.3M | 2.5M | 2.12M | 1.74M | 1.36M |
| Long-term Investments | 0 | 0 | 265K | 2.54M | 250K |
| Tax Assets | 0 | 0 | 0 | 896K | 0 |
| Other Non-current Assets | 0 | 0 | 0 | 0 | 500K |
| Total Non-current Assets | 3.49M | 5.41M | 6.32M | 9.25M | 5.84M |
| Total Assets | 62.54M | 67.86M | 78.05M | 87.33M | 81.42M |
| Account Payables | 2.41M | 1.53M | 1.67M | 2.15M | 2.31M |
| Short-term Debt | 0 | 340K | 565K | 545K | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 3.15M | 4.11M | 5.52M | 5.56M | 15.67M |
| Total Current Liabilities | 10.58M | 12.4M | 16.97M | 15.6M | 17.98M |
| Long-term Debt | 31.49M | 39.92M | 40.52M | 41.12M | 55.65M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 756K | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 380K | 31K | 0 | 0 | 1.48M |
| Total Non-current Liabilities | 31.87M | 41.15M | 42.2M | 43.27M | 57.13M |
| Total Liabilities | 42.45M | 53.55M | 59.17M | 58.87M | 75.11M |
| Common Stock | 15K | 19K | 24K | 39K | 44K |
| Retained Earnings | (229.93M) | (274.23M) | (320.89M) | (358.73M) | (397.56M) |
| Accumulated OCI | (52K) | 150K | 91K | 90K | 91K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 20.1M | 14.31M | 18.88M | 28.46M | 6.31M |
| Total Debt | 31.49M | 41.46M | 42.77M | 43.06M | 55.65M |
| Net Debt | (12.44M) | (563K) | (3.96M) | (9.61M) | 4.81M |
TELA Bio, Inc.
NASDAQ:TELA
Intrinsic Alpha fair value
Locked
Current Price
$1.14
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.